Regulation of nuclear receptor activity is the focus of numerous ongoing studies to develop novel therapies for the treatment of hormone-related cancer. Although cyclin D1 functions to control the activity of several nuclear receptors, the region(s) of the protein responsible for such transcriptional comodulation remain poorly defined. Herein, we map the region of cyclin D1 required for binding and repression of the androgen receptor (AR) to a central, exclusively a-helical domain. Deletion of this domain disrupted AR binding and corepressor activity. Further investigations showed that this domain is sufficient for AR interaction and possesses the ability to bind histone deacetylase 3. Strikingly, overexpression of this repressor region attenuates cell cycle progression in prostatic adenocarcinoma cells. The requirement of this domain for nuclear receptor repression was conserved with respect to thyroid hormone receptor beta-1, whereas cyclin D1 activation of the estrogen receptor occurred independently of the central region. Together, these data identify a minimal repression module within cyclin D1 and demonstrate that the coactivator and corepressor functions of cyclin D1 are distinct. In addition, our data suggest that properties of the cyclin D1 central domain could be exploited to develop novel prostate cancer therapeutics.
Introduction
Cyclin D1 regulates a variety of transcriptional programs through distinct mechanisms. Cyclin D1 was first identified based upon its critical role in promoting cell cycle progression (Arnold et al., 1989; Motokura et al., 1991; Rosenberg et al., 1991) . In this context, cyclin D1 regulates the transcriptional repressor function of the retinoblastoma tumor suppressor protein, RB (Kato et al., 1993) . Prior to mitogenic stimulation, RB forms repressor complexes on target gene promoters required for S-phase progression (e.g. cyclin A, thymidylate synthase) (reviewed in Dyson, 1998) . To induce proliferation, mitogens stimulate the expression and stabilization of cyclin D1. Accumulated cyclin D1 binds and activates cyclin-dependent kinases 4/6 (CDK4/6), directing the phosphorylation of RB. This phosphorylation event contributes to the disruption of RB repressor complexes and promotes expression of downstream target gene promoters (Mittnacht, 1998) . The ability of cyclin D1 to disrupt RB repressor complexes is required for cell cycle progression into S phase, thus highlighting the importance of cyclin D1 action in cellular proliferation (Bartkova et al., 1998) . However, it is increasingly apparent that cyclin D1 regulates a multitude of additional transcription factors independent of CDK4 and outside of its role in the cell cycle (e.g. v-Myb, DMP1, Sp-1, Myo-D, androgen receptor (AR), estrogen receptor alpha (ERa), and thyroid hormone receptor b (TRb1)) (reviewed in Coqueret, 2002; Ewen and Lamb, 2004) . Interestingly, these cell cycle-independent roles of cyclin D1 appear to play significant functions in oncogenesis (Lamb et al., 2003) . For example, ectopic expression of the cyclin D1-KE allele, defective in CDK binding, in mammary epithelial cells (MCF-7) confers a similar transcriptional profile to that observed with ectopic expression of the wild-type protein (Lamb et al., 2003) . In addition, B-cell lymphomas overexpressing cyclin D1 have been reported to maintain hypophosphorylated RB (Zukerberg et al., 1996) . Thus, the tumorigenic properties of cyclin D1 are likely to be linked to its role as a transcriptional regulator. Still, the mechanism by which cyclin D1 exerts control over the action of many of these factors remains poorly defined.
Nuclear receptors are currently the most widely studied family of cyclin D1-regulated factors. Specifically, cyclin D1 has been linked to the regulation of ERa, TRb1, PPARg, and AR (Neuman et al., 1997; Zwijsen et al., 1997 Zwijsen et al., , 1998 Knudsen et al., 1999; Lin et al., 2002; Petre et al., 2002; Petre-Draviam et al., 2003; . Although the response of these receptors to cyclin D1 action is varied, they are each highly regulated by association with their respective ligands. Conventionally, ligand association causes nuclear receptor release from inhibitory heat shock proteins, allowing the subsequent formation of active dimer complexes (Pratt and Toft, 1997) . Such activated nuclear receptor complexes bind target DNA elements with high affinity and facilitate the recruitment of coactivators required for target gene transactivation (reviewed in Khan and Nawaz, 2003) . Interestingly, cyclin D1 is known to activate ERa in a ligandindependent fashion through recruitment of coactivators (SRC-1 or P/CAF) to the receptor complex (Neuman et al., 1997; Zwijsen et al., 1997 Zwijsen et al., , 1998 McMahon et al., 1999) . This activity of cyclin D1 is manifested through its C-terminal 254 LxxLL 259 motif, a nuclear receptor interaction domain common to many coactivators (including SRC-1) (Zwijsen et al., 1998) . Through this mechanism, cyclin D1 is perceived to enhance ligand-dependent ERa transactivation in mammary carcinoma cells (Zwijsen et al., 1997) . In addition, recent evidence suggests that cyclin D1 antagonizes the activity of the transcription factor, C/EBPb, in a cell cycle-independent fashion to contribute to the oncogenesis observed in overexpressing mammary carcinoma cells (Lamb et al., 2003) . In contrast to its action in driving mammary oncogenesis and function as an ERa coactivator, cyclin D1 also acts as a potent corepressor of TRb1, PPARg, and AR (Lin et al., 2002; .
We, as well as others, have previously demonstrated that cyclin D1 plays a critical role in regulating androgen-dependent prostate growth. AR transactivation is regulated in a cell cycle-dependent manner, wherein at the G1/S boundary (where cyclin D1 expression is highest) receptor activity is significantly diminished (Martinez and Danielsen, 2002) . Indeed, a specific interaction between AR and cyclin D1 has been detected in primary liver tissue as well as prostate cancer cell lines, suggesting a physiological role for such an interaction in the regulation of androgen-dependent proliferation (Burd et al., in revision; Reutens et al., 2001) . We initially demonstrated that cyclin D1 binds directly to the AR N-terminus and specifically inhibits its ligand-dependent transactivation functions (Petre et al., 2002) . This corepressor activity was maintained in multiple cellular contexts and on all AR targets examined, thus demonstrating the potency of cyclin D1 action (Petre-Draviam et al., 2003) . In these studies, complete inhibition of AR transactivation was achieved at a 1 : 1 molar ratio of cyclin D1 to receptor, indicating that cyclin D1 can regulate AR at stoichiometric levels (Knudsen et al., 1999; Petre-Draviam et al., 2003) . Furthermore, we showed that ectopic expression of cyclin D1 in androgen-dependent prostatic adenocarcinoma cells inhibits their proliferation (Petre et al., 2002) , suggesting that mimetics of cyclin D1 action may prove useful to block AR activity, a major goal of prostate cancer therapy. Therefore, understanding the mechanisms of cyclin D1 action is of critical importance.
The cyclin D1 protein itself has yet to be crystallized, but its overall structure can be inferred from that of homologous viral (V, M, and K) and mammalian (A and H) cyclins (Brown et al., 1995; Kim et al., 1996; Card et al., 2000; Schulze-Gahmen and Kim, 2002) . A conserved cyclin box domain consisting of five tightly packed alpha helices lies within the cyclin D1 N-terminal fragment (Jeffrey et al., 1995) . It is through interaction of this domain with CDK 4/6 that the complex becomes competent for CDK-activating kinase (CAK) phosphorylation and subsequent activation (Morgan, 1995) . In addition, sequences within the cyclin D1 C-terminal PEST domain are known to regulate cyclin D1 localization and degradation (Diehl et al., , 1998 . Although numerous studies have linked these functional domains to the cell cycle-related functions of cyclin D1, few have examined the role of such regions in transcriptional regulation.
Herein, we identify the region of cyclin D1 responsible for both AR binding and repression and determine its role in regulating other nuclear receptors. We have localized the cyclin D1 corepressor domain to residues 142-253. Deletion of this domain resulted in compromised AR binding and corepressor activity, without perturbing the integrity of the cell cycle in transfected cells. Moreover, this central region proved sufficient for binding to both histone deacetylase 3 (HDAC3) and AR. Together, these data identify the central domain of cyclin D1 to be responsible for AR regulation. Consistent with the hypothesis, ectopic expression of the cyclin D1 central domain sufficiently hindered androgen-dependent growth in prostatic adenocarcinoma cells. Additionally, we probed the requirement of this domain for the regulation of additional nuclear receptors and assessed the impact of the central domain on cyclin D1 regulation of both ERa and TRb1. We demonstrated that the function of the cyclin D1 repressor module is conserved and that this function can be dissected from its coactivator activity. These findings indicate that nuclear receptor modulation is manifested through distinct cyclin D1 motifs. Moreover, these data identify a repressor domain within cyclin D1 and establish the impact of this motif on nuclear receptor function.
Results

Residues 142-253 are required for cyclin D1-androgen receptor interactions
We previously demonstrated that cyclin D1 interacts directly with the AR N-terminus to potently inhibit transactivation of androgen responsive genes (Knudsen et al., 1999; Petre et al., 2002; Petre-Draviam et al., 2003) . This corepressor activity of cyclin D1 is independent of RB and CDK association and does not require the LxxLL domain previously demonstrated to be essential for ERa coactivator activity (Zwijsen et al., 1998; Petre et al., 2002) . In order to determine the region(s) of cyclin D1 responsible for AR interaction, specific cyclin D1 deletion mutants ( Figure 1a ) were generated in a baculovirus expression system and immobilized by immunoprecipitation on protein-A beads. CD44 (negative control) and AR proteins were then generated by in vitro transcription/translation in the presence of [ 35 S]methionine and added to the bead-conjugated cyclin D1, as indicated. Binding reactions were washed and subjected to SDS-PAGE along with input proteins. Input and bound radiolabeled proteins were detected via autoradiography. As anticipated, CD44 failed to interact with any of the cyclin D1 derivative proteins (Figure 1b, lanes 1, 3, 5, and 7) . In contrast, AR effectively bound wild-type cyclin D1 as well as the D1-99 mutant (see lanes 2 and 4). Binding of the D61 mutant was slightly reduced, but maintained (see lane 6). Cyclin D1-DXMN, however, failed to associate with AR in vitro, indicating that the AR binding domain may lie within this region (lane 8). Expression and efficient immunoprecipitation of the cyclin D1 constructs were verified in parallel by SDS-PAGE followed by immunoblot analysis (Figure 1b, bottom panel) . Both wild-type and mutant cyclin D1 proteins were effectively expressed and immunoprecipitated. Thus, failure of cyclin D1-DXMN to bind AR suggests that the deleted central region (amino acids (aa) 142-253) is required for the in vitro association of these two proteins.
To further examine the requirement of this region for AR binding, we analysed cyclin D1-AR interactions through co-immunoprecipitation experiments. Here, COS-7 cells were transfected with AR and either cyclin D1 or cyclin D1-DXMN. Transfected cells were then harvested, lysed, and incubated with antisera generated against AR, DBF4 (negative control), or cyclin D1. Complexes were then subjected to SDS-PAGE followed by immunoblotting as indicated ( Figure 1c ). As expected, wild-type cyclin D1 efficiently associated with AR (lane 1), and AR co-immunoprecipitated with cyclin D1 (lane 3). In contrast, cyclin D1-DXMN failed to co-immunoprecipitate with AR in both the forward and reverse experiments (Figure 1c , lanes 4 and 6). Together, these data clearly demonstrate that the association of cyclin D1 with AR requires aa 142-253. Cyclin D1 wild-type and mutant proteins were expressed and purified using a baculoviral expression system. The proteins were immunoprecipitated and incubated with radiolabeled AR generated by in vitro transcription/translation. Following incubation, the beads were washed extensively and subjected to SDS-PAGE in duplicate. One gel (top) was dried and bound AR detected via autoradiography. The duplicate gel (bottom) was transferred and immunoblotted for cyclin D1 wild-type and mutant proteins. (c) COS-7 cells were transfected with either wild type (left panel) or cyclin D1-DXMN (right panel) and AR at a 1 : 1 ratio as described in Materials and methods. At 24 h post-transfection, cells were harvested and lysates subjected to immunoprecipitation with antibody directed against either cyclin D1, AR, or nonspecific (NS) protein. Following binding, reactions were washed and prepared for SDS-PAGE analysis. Transferred gels were cut in half and immunoblotted for AR and cyclin D1
Compromised corepressor function by the cyclin D1-DXMN mutant Since cyclin D1-DXMN is severely compromised for AR binding, we hypothesized that its AR corepressor activity would be similarly compromised. To assess the consequences of the 142-253 deletion, we employed mammalian expression constructs encoding wild type or cyclin D1-DXMN in reporter assays using the PSA-61-LUC reporter construct (6.1 kb of the prostate-specific antigen (PSA) promoter linked to luciferase; Cleutjens et al., 1997) to monitor AR activity. CV1 cells, which express no endogenous AR (data not shown), were transfected with reporter, human AR, CMV-b-galactosidase (internal control for transfection efficiency) and cyclin D1 (wild type or mutant) or empty vector (pCDNA3). These conditions were previously demonstrated by our laboratory to achieve a 1 : 1 molar ratio of cyclin D1 to AR protein in transfected cells (PetreDraviam et al., 2003) and mediate complete inhibition of the receptor as determined by titration experiments (Knudsen et al., 1999) . Following transfection, cells were stimulated for 24 h with 0.1 nM 5-a dihydrotestosterone (DHT) or 0.1% ethanol vehicle as indicated. Luciferase activity was monitored and normalized to b-galactosidase. Relative luciferase activity is shown and represents at least three independent experiments performed in triplicate. As expected, cyclin D1 effectively inhibited AR transactivation reducing its activity by approximately 92% (Figure 2a) . However, cyclin D1-DXMN failed to significantly inhibit AR corepressor activity. To verify that diminished cyclin D1 corepressor activity was not due to instability of the central domain deleted mutant protein, parallel immunoblots were performed. Lysates from parallel transfections wherein H2B-GFP was substituted for CMV-b-galactosidase were subjected to SDS-PAGE followed by immunoblotting. Proteins were detected via autoradiography using goat anti-rabbit horseradish peroxidase-conjugated antibodies and enhanced chemiluminescence enhancer. Although both endogenous and ectopically expressed cyclin D1 alleles were detected upon extended film exposure (data not shown), shorter exposures were utilized to assess the relative expression of the transfected alleles. As shown in Figure 2b , cyclin D1-DXMN and cyclin D1 wild type were equally expressed. In addition, these data reveal that the level of AR remained unchanged in the presence of either construct, verifying that the inhibitory action of cyclin D1 does not involve regulation of AR protein levels (Petre et al., 2002) . Thus, failure of cyclin D1-DXMN to repress AR transactivation is not due to protein Figure 2 Cyclin D1-DXMN demonstrates compromised AR corepressor activity. (a) CV1 cells were seeded in steroid-free conditions and transfected with PSA-LUC reporter, AR, b-galactosidase, and wild-type cyclin D1 (WTD1) or cyclin D1-DXMN (DXMN). Posttransfection, cells were treated with 0.1 nM DHT or 0.1% ethanol vehicle for 24 h. Cells were harvested and analysed for b-galactosidase and luciferase activity. AR activity in the absence of ligand (ethanol; ETOH) was set to '1' with the average fold induction by DHT presented. Error bars represent the standard deviation. Experiments were performed at least three times in triplicate. (b) Cells were transfected and treated as in (a) with H2B-GFP in place of CMV-b-galactosidase. The mock sample was not transfected. Following treatment, cells were harvested and subjected to SDS-PAGE followed by immunoblotting for AR, GFP, and cyclin D1 (wild type and DXMN). Data shown represent an autoradiography wherein the transfected alleles fall within the linear range of the film. (c) Vector (pCDNA3), wild-type cyclin D1, or cyclin D1-DXMN was transfected into CV1 cells along with H2B-GFP. At 24 h post-transfection, cells were harvested, fixed, and stained with PI to detect DNA content. Traces shown reflect the cell cycle profile of at least 10 000 transfected (GFP positive) cells instability or deregulated AR expression. However, it has been shown that AR activity is regulated in a cell cycle-specific manner (Martinez and Danielsen, 2002) . Although regions within the central domain were not previously reported to disrupt CDK binding, the integrity of threonine 156 appears to dictate CAK association and activation of the cyclin D1-CDK complex . To ensure that ectopic expression of cyclin D1-DXMN did not cause cell cycle arrest within a phase of high AR activity (e.g. a the G1/S transition), flow cytometry was performed. Specifically, CV-1 cells were transfected with H2B-GFP and vector (pCDNA), wild-type cyclin D1, or cyclin D1-DXMN. At 24 h post-transfection, cells were harvested, fixed, and stained with propidium iodide (PI) to determine DNA content. Flow cytometry was performed and both GFP-positive (transfected) and -negative (nontransfected) cells from the same plate were analysed. Histograms represent at least 10 000 cells analysed. Transfection with either wild type or cyclin D1-DXMN did not significantly alter the cell cycle profile relative to the control, vectortransfected samples ( Figure 2c ). In addition, this experiment was performed in COS-7 cells, revealing similar results, wherein the cell cycle profile was not modulated by transfection of either wild type or cyclin D1-DXMN (data not shown). Therefore, our data confirm that deletion of the cyclin D1 central domain does cause cell cycle arrest at the G1/S transition, but compromises its ability to bind AR and regulate its transcriptional activity.
Multiple sequences within the cyclin D1 central domain (aa 142-153) mediate AR binding and regulation
The central domain of cyclin D1 encodes a largely understudied region of the protein. Due to its high level of homology with known viral (V, K, and M) and mammalian cyclins (A and H), homology modeling can be used to obtain a putative three-dimensional structure of cyclin D1 or one can simply use sequence-to-structure alignment in order to build a model for the backbone conformation. As noted in other cyclins, the central domain of cyclin D1 contains a linker domain (aa 148-156) followed by five sequential alpha helices (aa 157-251) (Brown et al., 1995; Kim et al., 1996; Card et al., 2000; Schulze-Gahmen and Kim, 2002 ; see also Figure 4 ). In order to identify a specific AR-interacting motif within this cyclin D1 domain, we developed numerous internal deletion constructs and tested them for functional competency. To assess the binding capacity of these mutants, GST-AR1-660 was generated and purified on glutathione agarose. Cyclin D1 mutant and wild-type proteins were then obtained through transfection of COS-7 cells with pCDNA3.1-based constructs as shown in Figure 3a . At 24 h posttransfection, the lysates were harvested and incubated with immobilized GST-AR1-660. Following binding, the reactions were washed, samples prepared for SDS-PAGE analysis, and subsequently transferred to PVDF membrane. The resulting membranes were then immunoblotted with antibodies directed against the AR N-terminus and cyclin D1 C-terminus, as these epitopes are present in the truncated AR and internally deleted Figure 3 The central domain of cyclin D1 is required in its entirety to bind and regulate AR activity. (a) Schematic representations of cyclin D1 deletion mutants internal to aa 142-253 utilized in binding and functional assays. (b) COS-7 cells were transfected with wild-type or cyclin D1 mutant proteins as described in Materials and methods. Post-transfection, cells were harvested and lysates incubated on a column of GST-AR1-660. Following binding, the reactions were washed extensively and input (I) and bound (B) fractions subjected to SDS-PAGE analysis. The gels were transferred, cut in half, and immunoblotted for AR and cyclin D1. (c) Wild-type and mutant cyclin D1 proteins were generated via in vitro transcription/translation and subjected to binding with GST or GST-AR1-660 as in (a). Following binding, the reactions were washed, prepared for SDS-PAGE, and visualized as in (a). (d) CV1 cells were seeded, transfected, and treated as in Figure 2a . Samples were harvested and analysed for b-galactosidase and luciferase activity. Bars represent the average percent inhibition of wild-type AR activity. Error bars represent standard deviation. Experiments were performed at least three times in triplicate cyclin D1 proteins. As expected, wild-type cyclin D1 bound to the GST-AR1-660 column, whereas cyclin D1-DXMN demonstrated compromised binding capacity ( Figure 3b , bottom panel; compare lanes 4 and 6). Interestingly, overlapping N-or C-terminal deletions within the cyclin D1 central domain (D142-152, D152-174, D174-253) retained the capacity to bind the AR Nterminus, thus indicating that multiple contact sites may be present within this region ( Figure 3b , bottom panel; see lanes 8, 10, and 12). As cellular lysate contains potential bridging factors that may enhance the cyclin D1-AR interaction, we performed additional in vitro binding assays utilizing GST-AR1-660 and in vitrotranscribed/translated cyclin D1 alleles. While wild-type cyclin D1 effectively bound GST-AR1-660 in these assays (Figure 3c, lanes 1-3) , binding of cyclin D1-DXMN, D152-174, and D174-253 was undetectable (see lanes 4-12). Thus, it appears that the cyclin D1-AR interaction is potentially stabilized by other cellular bridging factors through sequences within the central domain. Additionally, these data reveal that the AR-cyclin D1 interaction is only compromised upon complete deletion of the central domain (aa 142-253).
To assess the AR corepressor function of each subdeletion, reporter assays were performed in CV1 cells transfected with PSA-61-LUC, pCMV-AR, CMVb-galactosidase, and expression plasmid encoding either cyclin D1 wild type, internal central domain deletion constructs, or empty pCDNA3 vector. Following transfection, cells were stimulated for 24 h, harvested, and assayed as described in Figure 2a . The percent inhibition was determined relative to AR activity in the presence of ligand and absence of cyclin D1. Bars represent the average inhibition from at least three independent experiments performed in triplicate. Wildtype cyclin D1 effectively reduced AR activity on the PSA promoter to basal levels (B88.9% repression), whereas cyclin D1-DXMN demonstrated compromised AR corepressor activity (B12.7% repression) (Figure 3d ). AR activity was actually enhanced in some assays, thus resulting in the standard deviation observed. Internal deletion of aa 142-152 had no effect on the ability of cyclin D1 to inhibit AR transactivation, supporting the hypothesis that these residues are dispensable for AR interaction. Deletion of N-or C-terminal regions within the central domain (D152-174, D174-253) slightly reduced cyclin D1 inhibition (B67.0 and B60.0%, respectively), supporting a model wherein several binding sites within the central domain mediate AR binding. However, in contrast to cyclin D1-XMN, severe aberrations in cell cycle progression were observed upon transfection of several other internal central domain deletion mutants (D152-253 and D174-253, data not shown), causing an increased number of cells at the G2/ M border and therefore reducing the potential to assess AR corepressor function (data not shown) accurately. As such, deletion of the entire central domain (residues 142-253) is optimal for ablation of AR corepressor function.
Cyclin D1 repressor domain is sufficient for AR binding and inhibition of androgen-dependent LNCaP proliferation
Our data demonstrate that deletion of the cyclin D1 central domain yields a protein defective in its ability to bind and regulate AR. Although this domain appears to be folding into a separate structural module (see Figure 4b ), it remains possible that elimination of this region alters the conformation of neighboring domains, thus abrogating cyclin D1-AR interaction. We previously mapped cyclin D1 binding to the first 34 aa of AR (Burd et al., in revision) . The predicted secondary structures and solvent accessibilities of residues in this AR region are depicted in Figure 4c . This prediction allows one to formulate specific hypotheses regarding the mode of cyclin D1-AR interaction (see also Discussion). When examining the role of the DXMN mutation in cyclin D1-AR interaction, it is of note that the region linking the cyclin box to the central domain and several residues forming the last a-helix of the cyclin box are deleted in this allele ( Figure 1a) . However, the cyclin box motif removed in the cyclin D1-DXMN mutant (residues LLVNKLK) is replaced by a similar C-terminal motif (residues LLESSLR). Therefore, this fragment is likely to adopt a similar conformation in the deletion construct, preserving the ability of cyclin D1 to bind CDKs and linking the cyclin box directly with the C-terminal (glutamic acid rich) signaling domain (see Figure 4a and c). The above hypothesis is addressed experimentally in two steps: we first show that the putative repressor domain is sufficient for AR binding and then we demonstrate that cyclin D1-DXMN maintains its coactivator activity in the absence of this central region.
In order to test the sufficiency of the putative repressor domain for AR binding, GST-repressor domain (aa 141-250 of cyclin D1 fused to the C-terminus of GST; GST-RD), GST-cyclin D1, and GST alone were generated and purified on glutathione agarose. AR was subjected to in vitro transcription/ translation in the presence of [
35 S]methionine and added to each reaction. Following binding, the columns were washed and both input and bound fractions were subjected to SDS-PAGE. The resulting gel was dried and bound AR detected on a Phospho Imager. In addition, aliquots of glutathione-bound GST proteins were subjected to SDS-PAGE and Coomassie stained to verify protein production and purification. The repressor domain of cyclin D1 bound AR with an efficiency comparable to that observed in the presence of wild-type protein ( Figure 5 ; compare lanes 2 and 3). GST alone, however, failed to bind AR, demonstrating the low background binding observed in this experiment (lane 4). In addition, co-immunoprecipitation experiments utilizing a GFP-tagged repressor domain confirmed these findings in vivo (data not shown). Thus, these data demonstrate sufficiency of the cyclin D1 repressor domain for AR binding.
Since the repressor domain is sufficient for AR interaction, we hypothesized that cyclin D1 corepressor activity would also be maintained within this module. In order to test this hypothesis, we examined the impact of GFP-RD expression upon the proliferation of androgen-dependent prostatic adenocarcinoma (LNCaP) cells. These cells are dependent on AR activity for proliferation and we have previously shown that ectopic cyclin D1 attenuates both AR-dependent transcription and AR-dependent proliferation (as monitored by bromodeoxyuridine (BrdU) assays) in this model system (Petre et al., 2002; Petre-Draviam et al., 2003) . To test the ability of the repressor domain to modulate androgen-dependent growth, LNCaP cells were transfected with GFP, GFP-cyclin D1, or GFP-RD, and GFPpositive cells were monitored for S-phase progression in the presence of androgen (complete serum) via BrdU incorporation assays. Data shown represent at least two independent experiments performed in triplicate. LNCaP cells transfected with GFP-RD demonstrated a significantly lower proliferation index than those transfected with GFP alone (Figure 5b ; B30.0 vs B52.3% BrdU incorporation). Interestingly, transfection with GFP-wild-type cyclin D1 caused a similar decrease in S-phase progression (B38.9% BrdU positive) and confirmed our previously reported results (see Figure 4 Structural analysis of cyclin D1 and the AR N-terminus. (a) Two-dimensional model of cyclin D1 structure as predicted by combination of sequence to structure alignment and secondary structure/solvent accessibility prediction, as described in Materials and methods. Arrows and braids respectively represent b-strands and a-helices, and the relative solvent accessibility of each amino-acid residue is depicted by shaded boxes. Black boxes indicate buried residues, whereas white boxes represent fully exposed residues. Amino acids composing the cyclin D1 repressor domain are highlighted in blue and the residues in contact with Cdk6 in red. (b) The overall three-dimensional structure of the cyclin D1 homolog, cyclin K, in complex with CDK6 (PDB code 1G3N). CDK6 is shown in blue, the N-terminal HN1 helix and the cyclin box domain in red, and the cyclin K counterpart to the cyclin D1 repressor domain (CD) in yellow. Note that cyclin K lacks the C-terminal signaling domain that extends from the last helix of the repressor domain in cyclin D1 (compare with panel a). (c) Two-dimensional model of the AR N-terminus (aa 1-50) generated as described in Materials and methods. The secondary structures and solvent accessibilities are represented as in (a) Petre et al., 2002) . Therefore, overexpression of the repressor domain itself abrogates cell cycle progression in a manner similar to the full-length protein, verifying that the cyclin D1 repressor function lies within this region. To verify that the effects of GFP-RD could counterbalance the mitogenic activity of androgen alone, experiments were repeated in LNCaP cells deprived of steroid for 48 h (to induce cell cycle arrest) prior to transfection, androgen addition, and BrdU exposure. Unfortunately, no enhancement of GFP-RD repression was observed (52% incorporation for GFP alone vs 37% for GFP-RD, data not shown). Overall, these data demonstrate that the repressor domain of cyclin D1 is sufficient for AR binding and regulation of androgen-dependent growth, thus identifying a novel AR repression module within a largely unstudied region of cyclin D1.
We have also shown that the effect of cyclin D1 on AR activity can be partially reversed through inhibition of HDACs, thus suggesting that cyclin D1 may recruit HDACs to the AR complex (Petre et al., 2002) . Subsequently, it was demonstrated that cyclin D1 can bind to HDAC3 and recruit this repressor molecule to the TRb1 complex (Lin et al., 2002) . Given our observation that the repressor domain is sufficient for corepressor activity, we hypothesized that HDAC3 may bind to this region of cyclin D1. To test this hypothesis, COS-7 cells were transfected with expression plasmids encoding GFP-cyclin D1 or GFP-RD and HDAC3. Transfected cells were harvested and lysates subjected to co-immunoprecipitation experiments, as shown ( Figure 5c ). Immunoprecipitation of GFP-cyclin D1 or GFP-RD complexes revealed a strong association with HDAC3, which was also noted in the reverse reaction (see lanes 1, 3, 4, and 6). Control antibody (DBF4), however, failed to pull down either HDAC3, GFPcyclin D1, or GFP-RD (lanes 2 and 5). Additionally, coimmunoprecipitations were performed in COS-7 cells transfected with GFP-RD alone to detect interaction of this peptide with endogenous HDAC3. Supporting our previous findings, GFP-RD complexes clearly demonstrated interaction with the endogenous protein (Figure 5d ). Thus, wild-type cyclin D1 as well as the cyclin D1 repressor domain alone binds HDAC3 specifically, uncovering one potential mechanism by which this domain mediates AR corepression.
Cyclin D1 repressor domain mediates nuclear receptor corepressor but not coactivator activity Since cyclin D1 has been reported to both positively (e.g. ERa) and negatively (e.g. TRb1) regulate selected nuclear receptor activity, we examined the role of the repressor domain in each of these functions (Neuman et al., 1997; Zwijsen et al., 1997 Zwijsen et al., , 1998 McMahon et al., 1999; Lin et al., 2002) . Specifically, regulation of TRb1 has been shown to occur through recruitment of HDAC3 to thyroid hormone responsive genes (Lin et al., 2002) . To assess the consequence of repressor domain deletion upon the repression of other nuclear receptors by cyclin D1, reporter assays were performed in CV-1 cells transfected as in Figure 2a with TRb1 and 8 Palaa-LUC (Figure 6a ). The 8 Palaa-LUC reporter construct contains two copies of 8 Pal, a palindromic thyroid hormone responsive element (TRE) with two perfect octameric half-sites, upstream of luciferase. Transfected cells were treated for 24 h with either 10 nM thyroid hormone (T3) or 500 mM sodium hydroxide (vehicle). In the absence of cyclin D1 expression, T3 activated TRb1 transcription approximately 5.5-fold. As shown, cyclin D1 significantly blocked TRb1 activity (Figure 6a ; Po0.05). By contrast, cyclin D1-DXMN Figure 5 The repressor domain is sufficient for AR binding and inhibition of LNCaP proliferation. (a) GST-repressor domain (GST-RD), GST-cyclin D1 (wild type), and GST were generated and purified as described in Materials and methods. In vitrotranslated AR was incubated on the columns and then washed to remove the unbound fraction. Input and bound fractions were subjected to SDS-PAGE analysis and visualized on a phosphoimager (top panel). The lower panel represents Coomassie staining of beads utilized for binding analysis. (b) LNCaP cells were transfected with GFP, GFP-cyclin D1, or GFP-RD as indicated. At 48 h post-transfection, cells were labeled overnight with BrdU, fixed, and stained. Histograms represent data from at least two independent experiments with error bars indicating the standard deviation. (c) COS-7 cells were transfected as in Figure 1c , with plasmids encoding HDAC3 and GFP-cyclin D1 or GFP-RD at a 1 : 1 DNA ratio. At 48 h post-transfection, cells were harvested and subjected to immunoprecipitation with antibodies directed against GFP, HDAC3, or nonspecific protein (NS). Following binding, the reactions were washed extensively and then analysed by SDS-PAGE followed by immunoblotting as indicated. (d) COS-7 cells were transfected as in panel c with GFP-RD and vector (pCDNA). Cells were harvested and co-immunoprecipitations performed as in (c) demonstrated significantly reduced TRb1 corepressor activity (Po0.05). Thus, deletion of the repressor domain abrogates cyclin D1 repression of both AR and TRb1.
Since the coactivator function of cyclin D1 has been mapped to an LxxLL motif external to the repressor domain deletion (Zwijsen et al., 1998) , we hypothesized that ERa regulation would be retained in the presence of the cyclin D1-DXMN mutant. To test this hypothesis, reporter assays were performed in CV-1 cells transfected with ERa and the 3XERE-LUC reporter. At 48 h poststimulation with 10 nM estradiol (E2) or 0.1% ethanol vehicle, cells were harvested and reporter assays performed. E2 stimulated ERa activity approximately 4.6-fold over vehicle alone (Figure 6b ). This activity was significantly enhanced by expression of both wild-type cyclin D1 and cyclin D1-DXMN (5.8-and 6.7-fold, respectively, Po0.05) demonstrating maintenance of coactivator activity in the absence of the cyclin D1 repressor domain. Interestingly, ligand-independent activation of ERa was not noted in these assays as previously reported (Zwijsen et al., 1998) . This observation may be cell type or reporter dependent, as previous studies were conducted in U2OS and COS-7 cells, which display increased ligand-dependent coactivation by cyclin D1 (approximately 30-40-fold) and with the ERE-TATA-LUC reporter construct. Thus, cyclin D1 possesses two distinct mechanisms of nuclear receptor modulation. The cyclin D1 corepressor function and HDAC binding capacity appear to be conserved within the repressor domain, whereas coactivator activity lies fully outside of this region. In summary, our data identify a transcriptional corepressor motif within cyclin D1, capable of binding to both AR and HDAC3. Moreover, we demonstrate that this corepressor region is distinct from the coactivator function of cyclin D1, revealing dual functions for cyclin D1 in nuclear receptor modulation.
Discussion
Our data examining the cyclin D1 AR corepressor function identifies a critical and conserved nuclear receptor regulatory domain. We find that the central domain of cyclin D1 (aa 142-253) is critical for AR binding and that deletion of these residues abrogates cyclin D1 corepressor activity. Interestingly, we also demonstrate that this repressor domain directly interacts with HDAC3 and is sufficient for both AR binding and inhibition of androgen-dependent proliferation, implying that this region represents a minimal repression module. Further studies to examine the role of the cyclin D1 central domain in nuclear receptor regulation show that its corepressor function is conserved. Specifically, cyclin D1 lacking the AR corepressor domain also demonstrates compromised ability to inhibit TRb1 transactivation. However, nuclear receptor coactivation by cyclin D1 appears to be distinct from its corepressor function and clearly lies outside of the central domain. Specifically, our data show that ERa coactivation occurs in the absence of the repressor domain and support previous findings implicating a C-terminal LxxLL motif in nuclear receptor coactivation by cyclin D1. These data have significant mechanistic and clinical implications, showing that a small region of cyclin D1 encodes a nuclear receptor corepressor motif distinct from the cyclin D1 coactivator function and capable of limiting androgen-dependent proliferation.
The repressor domain of cyclin D1 is required and sufficient for AR binding
Although the crystal structure of cyclin D1 has yet to be solved, its homology with previously crystallized viral and human (K, M, A, and H) cyclins gives insight into its putative configuration (Brown et al., 1995; Kim et al., 1996; Card et al., 2000; Schulze-Gahmen and Kim, 2002) . Through such analysis, the cyclin box has been identified to lie within aa 56-152 of the protein, an area containing five distinct alpha helices (Jeffrey et al., 1995; Kim et al., 1996; Inoue and Sherr, 1998) . Within this N-terminal domain is the CDK4 binding site (K114), required for kinase activation and subsequent RB phosphorylation (Hinds et al., 1994 ) (see also Figure  4a and b). Immediately following the cyclin box is a short linker peptide and a second set of five sequential helices. It is within this functionally uncharacterized domain that we map the interaction of cyclin D1 with AR. We show that this domain is both required and sufficient for AR binding (Figures 1 and 5) . Our ongoing studies demonstrate that an N-terminal AR fragment (aa 1-34), whose computationally predicted secondary structures and solvent accessibilities are shown in Figure 4c , mediates the interaction with cyclin D1 (Burd et al., in revision) . As can be seen from Figure 4c and a, the solvent-exposed surfaces of the AR N-terminus (residues 17-33) and the repressor domain C-terminal helices (residues 238-253) appear to be complementary in terms of charged residue distribution. Therefore, one plausible mode of interaction between AR and cyclin D1 could involve packing of these two helical fragments against one another. It is intriguing that we previously demonstrated a similar AR corepressor activity for cyclin D3 (Knudsen et al., 1999) . The cyclin D1 central, repressor domain contains several regions with virtual identity to their cyclin D3 counterparts, including, but not exclusive to, aa 142-161, 178-192, and 242-252 (100% homology) . Indeed, it is possible that several of these homologous regions participate in AR binding or complex stabilization, as internal deletions of the cyclin D1 central domain demonstrate impaired AR binding and corepressor activity. Testing these hypotheses will be the subject of future work.
The role of the cyclin D1 254 LxxLL 259 motif in AR binding and regulation appears to be insignificant. The data herein further confirm our initial studies (Petre et al., 2002) demonstrating that cyclin D1 does not utilize an LxxLL domain for interaction with its highaffinity binding site within the AR N-terminus. Interestingly, we, as well as others, have reported an 254 LxxLL 259 -dependent interaction of cyclin D1 with AR that occurs only in the absence of the N-terminal binding site (Burd et al., in revision; Reutens et al., 2001) . This secondary interaction enhances the receptor C-terminal transactivation function, AF-2, hypothetically through the recruitment of coactivators (e.g. P/CAF and SRC-1) in a manner similar to that observed during ER coactivation by cyclin D1 (Burd et al., in revision) . In the context of the full-length receptor, however, cyclin D1 N-terminal binding and corepressor activity are dominant, suggesting that LxxLL-mediated C-terminal interactions have little or no biological relevance (Burd et al., in revision) . In addition, we find that deletion of cyclin D1 aa 142-152, which contain a second, putative nuclear receptor interaction motif (   142   LLLxxxLxxxL   152 ), also failed to compromise cyclin D1 corepressor activity (Figure 3c ). Point mutation of residues within this region (L142-144A) of cyclin D1 in the presence of the L254, 255A genotype also yielded a mutant capable of full AR repression (data not shown). Thus, taken together, these studies clearly demonstrate that an LxxLL motif is not required for physiologically relevant cyclin D1 binding and regulation of AR and instead suggest that several novel binding motifs present within its central domain are critical for AR corepression.
Interestingly, we also noted significant cell cycle aberrations caused by overexpression of cyclin D1 mutants internal to the central domain (data not shown). Amino acids within this domain have been shown to be required for proper phosphorylation of the CDK T-loop by CAK . In fact, mutation within this domain (T156A) compromises cyclin D1 function and also decreases its affinity for p21, a factor thought to be required for nuclear import of the cyclin-CDK complex . These previous findings may explain why such internal deletion within the cyclin D1 central domain caused defects in cell cycle progression only in the presence of the linker domain (data not shown). It is important to note that AR transactivation potential is cell cycle dependent, yet the regulation of other nuclear receptors throughout this process has yet to be examined (Martinez and Danielsen, 2002) . In a recent report by Marvada et al. (2004) , the translation and activity of TRb are also linked to cell cycle progression. Specifically, TRb transactivation is lowest at G0 and rises as the cell cycle progresses and TRb translation increases, ultimately peaking at G2/M. Our findings suggest that examination of both cell cycle-dependent and -independent roles of cyclin D1 is critical for proper interpretation of its comodulatory effects. In addition, it will be of interest to determine if other cyclin D1-regulated nuclear receptors including PPARg and/or ERa are regulated in a cell cycle-dependent manner.
Conservation of the cyclin D1 corepressor domain in nuclear receptor regulation
Recent evidence has linked cyclin D1 to the regulation of numerous transcription factors including many from the nuclear receptor superfamily. We previously demonstrated that ectopic cyclin D1 expression markedly decreases androgen-dependent proliferation (Petre et al., 2002) and herein show that this action can be mediated through the repressor domain alone (Figure 5b) . Furthermore, repressor domain interaction with HDAC3 (Figure 5c and d) and the ability of TSA to partially reverse cyclin D1 corepressor activity (Petre et al., 2002) suggest that it may serve as a scaffold to recruit HDAC activity to AR. HDACs (specifically HDACs 1-3) have been previously documented to inhibit AR transactivation potential (Gaughan et al., 2002 ), yet the mechanism by which the receptor associates with these corepressors remains somewhat unclear. In addition, although AR-HDAC1 interaction can be detected by both mammalian two-hybrid and co-immunoprecipitation assays, the requirement for accessory scaffolding factors has yet to be examined (Gaughan et al., 2002) .
Similar to our findings with AR, the mechanism of cyclin D1 inhibition of TRb1 activity has been recently linked to HDAC3 recruitment (Lin et al., 2002) . Here, we demonstrate that deletion of the cyclin D1 central domain abrogates cyclin D1 regulation of both TRb1 and AR, suggesting that a conserved mechanism of repression exists. As HDAC activity appears to be a required component for the regulation of both nuclear receptors, it is logical to hypothesize that central domain contains a conserved nuclear receptor corepressor motif. This hypothesis is further supported by a paper recently published by , wherein PPARg regulation by cyclin D1 is also mapped to a region within the central domain (aa 143-179). In addition, cyclin D1 binding to the DMP1 transcription factor was previously mapped to the central domain; however, the effect of the DXMN mutation on DMP1 regulation was never determined (Inoue and Sherr, 1998 ). Thus, it remains possible that the nuclear receptor corepressor motif of cyclin D1 is also utilized in the regulation of other transcription factors such as STAT3, v-Myb, and Sp1 (Shao and Robbins, 1995; Ganter et al., 1998; Bienvenu et al., 2001; Ratineau et al., 2002) . To date, the interaction motif required for regulation of these transcription factors has yet to be identified and, clearly, further investigations are needed to determine the overall significance of the cyclin D1 central domain in transcriptional corepression.
The central domain is dispensable for nuclear receptor coactivation
ERa was among the first transcription factors documented to be cyclin D1-regulated (Neuman et al., 1997; Zwijsen et al., 1997) . Herein, we find that deletion of the central domain compromises cyclin D1 corepressor but not coactivator activity. Interestingly, this mutant allele of cyclin D1 maintains the 254 LxxLL 259 motif, critical residues known to mediate the recruitment of coactivators such as P/CAF and SRC-1 and enhance ERa transactivation (Zwijsen et al., 1998; McMahon et al., 1999) . In addition, ectopic expression of a cyclin D1 allele defective in CDK binding (K114E) has been shown to produce a transcriptional profile correlative with that of the C/EBPb gene targets (Lamb et al., 2003) . These findings lead to the hypothesis that antagonism of C/EBPb is responsible for the majority of effects contributing to cyclin D1-mediated oncogenesis in mammary carcinoma cells (Lamb et al., 2003) . As our data demonstrate that the cyclin D1 coactivator function is separable from its ability to function as a corepressor, we suggest that these activities could be selectively targeted in cancer therapy. Thus, we propose that the oncogenic effects of cyclin D1 (ERa coactivation, C/EBPb regulation, and RB phosphorylation) are dispensable for nuclear receptor corepressor activity.
Repressor domain function can be exploited to block proliferation in AR-dependent cells
Although cyclin D1 is often amplified in numerous tumor types including mammary carcinoma, a recent report by Maddison et al. (2004) demonstrates a decline in cyclin D1 levels during prostate cancer progression in murine models. In addition, cyclin D1 is found localized to the cytoplasm of advanced human prostate cancers (Maddison et al., 2004) . Thus, these observations lead to the conclusion that the loss of cyclin D1 action is associated with tumor progression. Correspondingly, amplification or overexpression of cyclin D1 in prostate cancer is a rare event and cyclin D1 expression alone provides no prognostic value (Gumbiner et al., 1999; Drobnjak et al., 2000) . Thus, it appears that cyclin D1 regulation of AR activity may be subverted in late-stage cancers, providing a growth advantage to these tumors. We previously demonstrated that ectopic cyclin D1 expression attenuates the proliferation of androgendependent prostatic adenocarcinoma cells and suggested that this property might be exploited for the development of novel cancer therapeutics (Petre et al., 2002) . Herein, we define a small peptide constituting the central domain of cyclin D1 that maintains the growth inhibitory properties of the wild-type protein in ARdependent cell lines. Furthermore, our initial studies together with these data demonstrate that the coactivator and cell cycle stimulatory effects of cyclin D1 can be effectively dissected from its corepressor function. Thus, we have made a significant advance toward the development of small protein mimetics based on the structure and mechanism of cyclin D1 corepressor function.
In summary, we have identified the cyclin D1 nuclear receptor corepressor motif to reside within a central region (aa 142-253) within the protein. Ectopic expression of a cyclin D1 mutant lacking this domain fails to disrupt cell cycle profile, further supporting previous studies demonstrating that the cell cycle function of cyclin D1 is separable from its function in G1-S control. This region is sufficient for AR binding and contains several motifs that may contribute to the interaction and inhibition of nuclear receptor activity. Cyclin D1 corepressor activity appears distinct from its ability to coactivate other nuclear receptors, which may prove useful in the development of protein mimetics to block nuclear receptor function. In addition, current evidence suggests that the identified repressor module of cyclin D1 extends beyond nuclear receptor control, as the DMP1 transcription factor also interacts with this motif (Inoue and Sherr, 1998) . Together, the data shown here reveal a novel regulatory region of cyclin D1 and demonstrate that its role as a corepressor can be cleanly segregated from its function in cell cycle control or as a nuclear receptor coactivator. Given both the cell cycledependent and -independent roles of cyclin D1 hypothesized to regulate androgen-dependent growth, it will be of interest to determine if AR binding to this region is altered during prostatic tumorigenesis. Furthermore, it remains to be determined if this domain harbors additional clues to the development and progression of other disease states involving cyclin D1-regulated pathways and if novel therapeutics can be developed based on these studies that mimic cyclin D1 action.
Materials and methods
Cell culture and treatment CV1 and COS-7 cells were obtained from ATCC and cultured in DMEM supplemented with 10% heat-inactivated fetal bovine serum (DFBS; Atlanta Biologicals, Norcross, GA, USA), 100 U/ml penicillin/streptomycin (Mediatech, Herndon, PA, USA), and 2 mM L-glutamine. LNCaP cells from ATCC were maintained in IMEM supplemented with 5% DFBS, penicillin/streptomycin, and L-glutamine. For steroid-free conditions used in reporter assays, 10% charcoal-dextrantreated FBS (CDT; Hyclone Laboratories, Logan, UT, USA) was utilized.
Transfection and transcriptional reporter assays CV1 cells were seeded in the absence of steroid hormones and transfected with a total of 4 mg of DNA (0.75 mg reporter, 0.5 mg receptor, 0.5 mg CMV-b-galactosidase, 0.75 mg PCDNA vector and 1.5 mg (2.0 mg for TRb1 assays) cyclin D1 or additional vector) using the N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid calcium phosphate transfection protocol as previously described (Chen and Okayama, 1987) . Following overnight transfection, cells were washed and allowed to recover for 4-6 h prior to stimulation as indicated with 0.1 or 1 nM DHT (24-48 h, as indicated; Sigma), 10 nM 17-b-estradiol (48 h; Sigma), 10 nM T3 (24 h; Sigma), or 0.1% ethanol vehicle. Cells were then harvested, lysed, and monitored for luciferase activity using the Promega luciferase assay kit (Promega, Madison, WI, USA). b-Galactosidase activity was measured as an internal control for transfection efficiency using GalactoStar reagent (Tropix, Bedford, MA, USA). Appropriate P-values were obtained using ANOVA followed by a Newman-Kuels multiple comparison post-test.
To detect protein expression levels of cyclin D1 in reporter assays, CV1 cells were transfected in 6 cm dishes and GFPtagged histone 2B (H2b-GFP) substituted for CMV-b-galactosidase. Following treatment, cells were harvested and subjected to SDS-PAGE on a 10% polyacrylamide gel. The gel was then transferred to Immobilon (Millipore Corp., Bedford, MA, USA) and immunoblotted for GFP (Santa Cruz Biotechnology, Santa Cruz, CA, USA; B-2), AR (Santa Cruz Biotechnology; , and cyclin D1 (Neomarkers, Freemont, CA, USA; Ab-3). Proteins were detected via autoradiography using either goat anti-mouse (GFP) or goat anti-rabbit horseradish peroxidase-conjugated antibodies (Pierce, Rockford, IL, USA) and enhanced chemiluminescence enhancer (PerkinElmer Life Sciences, Boston, MA, USA). Exposures representing expression of the ectopic constructs within the linear range of the film were chosen. Upon longer exposure, endogenous cyclin D1 was detected (data not shown).
Plasmids
The pSG5-AR, H2b-GFP, CMV-b-galactosidase, PSA-61-LUC, pBS3XERE-LUC, p-CMV5-hERa, pGEX 3X cyclinD1-GST, pEGFP-cyclin D1a, and CMV-CD44 constructs were previously described (Petre et al., 2002; Petre-Draviam et al., 2003; Solomon et al., 2003) . GST-AR1-660 contains the first 660 aa of the wild-type AR fused to GST and was generously provided by E Wilson (University of North Carolina at Chapel Hill, Chapel Hill, NC, USA). The 8 Palaa-LUC thyroid hormone responsive luciferase reporter and receptor expression plasmid, pCDNA3.1-TRb1, were generously provided by Dr R Koenig (University of Michigan, Ann Arbor, MI, USA). pCDNA3-HDAC3-Flag was kindly supplied by Dr E Seto (University of South Florida, Tampa, FL, USA). Plasmid constructs encoding cyclin D1 variants (wild type, D1-99, D61, and DXMN) for baculoviral expression were previously described and kindly provided by Dr C Sherr (St Jude Children's Research Hospital, Memphis, TN, USA; Inoue and Sherr, 1998) . Plasmid encoding cyclin D1-DXMN (pBJ5-cyclin D1DXMN) for mammalian expression was previously described (Inoue and Sherr, 1998) . The pFlexFlag-cyclin D1D174-253 construct was made by removing aa 174-253 of pFlex-Flag-cyclin D1 by QuikChange PCR (Stratagene). To generate pCDNA3.1-cyclin D1 wild type, DXMN, and D174-253 constructs for mammalian expression, the cyclin D1 insert was first removed from the parental vector (pRSV-cyclin D1, pBJ5-cyclin D1DXMN (Inoue and Sherr, 1998) , and pFlex-FlagCycD1D174-253, respectively) via BamHI digestion. The inserts were then ligated into the BamHI site of pCDNA3.1 (Invitrogen) and screened for orientation. Additional mammalian expression constructs encoding cyclin D1D152-174, cyclin D1D152-153, and cyclin D1D142-152 were made using pCDNA3.1-cyclin D1 (wild type) as a template for the QuickChange Site-Directed Mutagenesis Kit as described by the manufacturer (Stratagene, La Jolla, CA, USA). GSTcyclin D1-repressor domain (GST-RD) was generated by PCR amplification of aa 141-250 of wild-type cyclin D1 using primers flanked by BamHI recognition sites. The generated PCR product was then inserted into the BamHI site in pGEX-KG (Guan and Dixon, 1991) . To generate GFP-tagged cyclin D1 repressor domain (pEGFP-RD), the PCR product utilized to make GST-RD was inserted into the BamHI site of pEGFP-C1 (Clontech, Palo Alto, CA, USA). All cyclin D1 mutants generated were verified by sequencing at the University of Cincinnati DNA core.
In vitro binding assays
For assays shown in Figure 1b , cyclin D1 wild-type and mutant proteins were generated using the baculovirus purification system as previously described (Summers, 1987; Gladden and Diehl, 2003) and lysed in NETN (20 mM Tris (pH 8.0), 100 mM NaCl, 1 mM EDTA (pH 8.0), and 0.5% Nonidet P-40) solution containing 1 mM phenylmethylsulfonyl fluoride, 10 mg/ml 1,10-phenanthroline, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 10 mM sodium fluoride, 1 mM sodium vanadate, and 60 mM b-glycerophosphate (PPI). Wild-type, D1-99, and D61 cyclin D1 proteins were subsequently immunoprecipitated on protein-A-Sepharose beads (Amersham) using 6 ml of cyclin D1-Ab3 (Oncogene) and 1 ml of rabbit anti-mouse (ICN) antisera. For cyclin D1DXMN, 2 ml of D1-17-13G (Gladden and Diehl, 2003) along with 1 ml of rabbit anti-mouse was utilized.
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S-labeled AR and CD44 proteins were made using the TnT-coupled Reticulocyte Lysate system (Promega) and then added to the immunoprecipitated reactions as indicated. In vitro transcription/translation of AR and CD44 proteins was carried out in the presence of NEG-772 Easytag Express Labeling Mix (PerkinElmer Life Sciences). Following incubation for 3 h at 41C with rotation, the reactions were washed five times in NETN þ PPI. The samples were then subjected to SDS-PAGE in duplicate. One 10% acrylamide gel was incubated in Fluoro-Hance solution (Research Products International Corp., Mount Prospect, IL, USA) as specified by the manufacturer, dried, and proteins were detected via autoradiography. The duplicate gel was transferred to Immobilon (Millipore Corp., Bedford, MA, USA) and immunoblotted for cyclin D1 using antibody directed against full-length cyclin D1 (Neomarkers, Freemont, CA, USA; Ab-3, Lot #010P010). Horseradish peroxidase-conjugated protein-A secondary antibody (Zymed) and enhanced chemiluminescence enhancer (PerkinElmer Life Sciences) were used to visualize proteins.
For GST-AR binding assays shown in Figure 3b , GST-AR1-660 and GST were generated and purified from bacteria using standard procedures. Lysates from COS-7 cells transfected with 16 mg of the indicated cyclin D1 expression plasmids were incubated with equal amounts of GST-AR or GST-conjugated agarose for 4 h at 41C. Following binding, the beads were washed five times in NETN þ PPI and prepared for SDS-PAGE. Transferred Western blots were probed for both cyclin D1 and AR. Autoradiographies represent film exposures wherein ectopic cyclin D1 expression falls within the linear range of detection. Endogenous cyclin D1 is visible upon longer exposure. GST in vitro binding assays shown in Figures 5a and 3c were preformed as previously described (Petre et al., 2002) . Bound AR was detected and visualized on a Storm 860 phosphoimager (Molecular Dynamics).
Co-immunoprecipitation assays
For co-immunoprecipitations, COS-7 cells were seeded in 10 cm dishes and transfected the following day using the BES/ calcium phosphate protocol (Chen and Okayama, 1987) . Cyclin D1 and pSG5-AR or GFP-cyclin D1/GFP-RD and HDAC3/pCDNA3 constructs were introduced at a 1 : 1 ratio with DNA concentrations totaling 16 mg. Post-transfection, cells were washed and allowed to recover for 24 h prior to harvest and lysed in 1 ml of NETN þ PPI. Lysates were sonicated and clarified by centrifugation before being divided equally among control (DBF4; Santa Cruz Biotechnology), AR (N-20; Santa Cruz), and cyclin D1 (Figure 1c ; Neomarkers) or control (DBF4 or E1A; Santa Cruz), GFP (Santa Cruz) and HDAC3 (Santa Cruz) immunoprecipitation reactions. Bound fractions were subjected to SDS-PAGE followed by Western blotting. Protein-A horseradish peroxidase-conjugated secondary antibody was utilized for protein visualization (Zymed, San Francisco, CA, USA).
Flow cytometry
CV1 and COS-7 cells were transfected with 16 mg of plasmid encoding vector (pCDNA3), cyclin D1 wild type, or cyclin D1-DXMN and 1.0 mg H2B-GFP. At 24 h post-transfection, cells were harvested and fixed in 80% ice-cold ethanol. Following fixation, cells were treated with RNase, stained with PI (0.2 mg/ ml), and subjected to flow cytometry to detect PI intensity in both the GFP-positive and -negative (mock) populations. Histograms represent approximately 10 000 GFP-positive cells.
BrdU incorporation
LNCaP cells were seeded on poly-L-lysine-coated coverslips in six-well dishes and transfected the following day using Lipofectin reagent (Invitrogen) and 2.0 mg of either GFP, GFP-cyclin D1, or GFP-repressor domain (GFP-RD). Following transfection, media were replaced and cells were allowed to recover for 32 h. Transfected cells were then pulsed overnight with BrdU (Amersham Biosciences), fixed, and stained to detect BrdU through indirect immunofluorescence as previously described (Petre et al., 2002) . Transfected (GFPpositive) cells were scored for BrdU incorporation and the results represent duplicate experiments performed wherein at least 80 cells were counted per well.
Structural analysis
Two-dimensional models of cyclin D1, as depicted in Figure 4a and c, were derived using a combination of sequence-tostructure alignments (for fragments corresponding to highly homologous cyclin domains of known structure) and secondary structure, as well as relative solvent accessibility prediction for the remaining fragments. The secondary structure of residues 22-261 of cyclin D1 is assigned based on alignment with the sequence of the highly homologous cyclin K, as defined by Card et al. (2000) . For illustration purposes, relative solvent accessibilities of residues in this region were assigned (without side-chain geometry optimization) based on the cyclin K-CDK6-INK4C crystal structure (PDB code 1G3N) (Jeffrey et al., 2000) . Relative solvent accessibilities, especially for at least partially exposed residues, vary widely between homologous structures and are strongly dependent on conformational changes induced by binding to different cofactors. Therefore, the actual solvent accessibilities are likely to be different, depending on the binding partners and the extent of conformational rearrangement. For the remaining N-and C-terminal cyclin D1 fragments, as well as the AR N-terminus (aa 1-50) depicted in Figure 4c , the secondary structures and solvent accessibilities were predicted by using the SABLE server . Figure 4a and c was generated using the POLYVIEW server , whereas Figure 4b with the structure of homologous cyclin K was obtained using the RASMOL program (Sayle and MilnerWhite, 1995) .
